XORTX Therapeutics Inc (TSE:XRTX)
:XRTX
Want to see TSE:XRTX full AI Analyst Report?
Top Page
XORTX Therapeutics Inc
(XRTX)
Select Model
Select Model
Rating:45Neutral
Price Target:
C$3.00
▲(284.62% Upside)
Action:Reiterated
Date:05/18/26
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and sustained cash burn), only partly offset by very low leverage and improving loss trends. Technicals are neutral-to-mixed, and valuation is difficult to support with a negative P/E and no dividend yield.
Positive Factors
Very low leverage
Extremely low reported debt materially reduces financial distress risk for a development-stage biotech. This structural balance sheet strength gives management flexibility to pursue R&D, licensing or partnerships without large interest burdens, supporting program continuity over months.
Negative Factors
No revenue and ongoing net losses
The absence of product revenue means the company relies on external capital to fund operations. Continued net losses undermine self-sufficiency and increase the likelihood of future financings, which can dilute shareholders and pressure long-term project continuity.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Extremely low reported debt materially reduces financial distress risk for a development-stage biotech. This structural balance sheet strength gives management flexibility to pursue R&D, licensing or partnerships without large interest burdens, supporting program continuity over months.
Read all positive factors
XORTX Therapeutics Inc (XRTX) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$4.04M
Dividend YieldN/A
Average Volume (3M)11.08K
Price to Earnings (P/E)―
Beta (1Y)0.37
Revenue GrowthN/A
EPS Growth-79.26%
CountryCA
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-10.94
Shares Outstanding1,392,444
10 Day Avg. Volume30,736
30 Day Avg. Volume11,079
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.75
Revenue Forecast (FY)C$3.25M
XORTX Therapeutics Inc Business Overview & Revenue Model
Company Description
Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering and bringing to market treatments for a variety of conditions, including progressive kidney disorders, diabetes, insulin resistance, metabolic...
How the Company Makes Money
null...
XORTX Therapeutics Inc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
44
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -84.04K | -114.08K | -111.64K | -141.96K | -75.27K | -17.88K |
| EBITDA | -2.14M | -3.20M | -3.04M | -6.00M | -9.41M | -2.90M |
| Net Income | -2.75M | -2.70M | ― | -2.86M | -6.99M | -1.65M |
Balance Sheet | ||||||
| Total Assets | 2.15M | 2.68M | 4.09M | 5.47M | 12.37M | 17.38M |
| Cash, Cash Equivalents and Short-Term Investments | 250.45K | 862.94K | 2.47M | 3.45M | 10.43M | 18.80M |
| Total Debt | 15.07K | 37.22K | 38.76K | 11.51K | 77.60K | 0.00 |
| Total Liabilities | 861.60K | 597.98K | 757.54K | 825.94K | 5.38M | 4.18M |
| Stockholders Equity | 1.28M | 2.08M | 3.33M | 4.64M | 7.00M | 13.20M |
Cash Flow | ||||||
| Free Cash Flow | -2.15M | -2.82M | -3.50M | -6.63M | -9.01M | -4.83M |
| Operating Cash Flow | -2.62M | -2.82M | -3.50M | -6.58M | -8.96M | -4.80M |
| Investing Cash Flow | -303.78K | -300.12K | -38.92K | -46.36K | -60.02K | -31.81K |
| Financing Cash Flow | 1.27M | 1.45M | 2.78M | -361.04K | 6.43M | 19.37M |
XORTX Therapeutics Inc Technical Analysis
Negative
0.78
Price Trends
3.29
Negative
3.19
Negative
4.03
Negative
Market Momentum
-0.12
Positive
40.86
Neutral
13.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:XRTX, the sentiment is Negative. The current price of 0.78 is below the 20-day moving average (MA) of 3.13, below the 50-day MA of 3.29, and below the 200-day MA of 4.03, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 40.86 is Neutral, neither overbought nor oversold. The STOCH value of 13.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:XRTX.
XORTX Therapeutics Inc Risk Analysis
XORTX Therapeutics Inc disclosed 85 risk factors in its most recent earnings report. XORTX Therapeutics Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
XORTX Therapeutics Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$5.82M | 0.79 | 123.88% | ― | ― | 60.66% | |
45 Neutral | C$4.04M | -1.05 | -111.11% | ― | ― | -79.26% | |
41 Neutral | C$5.46M | -2.46 | ― | ― | ― | ― | |
| ― | C$2.04M | -0.62 | ― | ― | ― | 25.09% | |
43 Neutral | C$1.68M | -2.19 | -41.36% | ― | 73.76% | -108.30% |
* Healthcare Sector Average
TSE:XRTX
XORTX Therapeutics Inc
2.90
-3.25
-52.85%
TSE:APS
Aptose Biosciences
2.28
-0.12
-5.00%
TSE:KNE
Kane Biotech
0.03
-0.03
-50.00%
TSE:QPT
Quest Pharmatech
0.03
-0.03
-45.45%
TSE:BIOV
BioVaxys Technology
0.07
-0.28
-80.00%
TSE:MOOD
Doseology Sciences
0.21
-0.11
-34.38%
XORTX Therapeutics Inc Corporate Events
Business Operations and StrategyM&A Transactions
XORTX Closes US$3 Million Deal for Vectus Kidney Anti-Fibrotic Program
Positive
Apr 13, 2026
XORTX Therapeutics has closed its acquisition of Vectus Biosystems’ renal anti-fibrotic program, securing VB4-P5, a novel small-molecule candidate aimed at treating both rare and common forms of chronic kidney disease. The pre-IND asset pack...
Business Operations and StrategyExecutive/Board ChangesShareholder MeetingsStock Split
XORTX Shareholders Approve Governance Measures and Share Consolidation at Annual Meeting
Positive
Mar 26, 2026
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company specializing in therapies for gout and kidney-related diseases, is advancing multiple programs that target uric acid production and purine metabolism, including late-stage candi...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
XORTX Delays Effective Date of One-for-Five Share Consolidation
Neutral
Mar 26, 2026
XORTX Therapeutics Inc. has postponed the effective date of its planned share consolidation, changing the timing of a one-for-five reverse stock split from March 27, 2026 to April 6, 2026. The corporate action remains contingent on receiving all n...
Delistings and Listing ChangesStock Split
XORTX Consolidates Shares in Bid to Maintain Nasdaq Listing
Negative
Mar 26, 2026
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company specializing in treatments for gout and kidney-related diseases, is advancing a portfolio of uric acid–targeting drug candidates, including late-stage programs for gout, A...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingShareholder Meetings
XORTX Reshapes Board to Meet Conditions for Planned Financing
Positive
Mar 18, 2026
XORTX Therapeutics Inc. plans to nominate three new directors, George Scorsis, Richard Grieve, and Mika Grasso, at its March 24, 2026 annual and special shareholder meeting, replacing three previously proposed nominees. The board changes are a con...
Business Operations and StrategyShareholder MeetingsStock Split
Proxy Advisers Back XORTX Share Consolidation Plan Ahead of March Vote
Positive
Mar 13, 2026
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, develops therapies for gout and progressive kidney disease, including advanced programs XRx-026, XRx-008 and XRx-101, plus a pre-clinical candidate for Type 2 diabetic nephropa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.